Additionally, we further confirmed that the interaction between MET and SRC and the formation of MET/SRC/EGFR complex contributed to constitutive MET activation, providing a rationale for combinatorial inhibition of EGFR and MET or EGFR and SRC in therapy targeting colon cancer. The gene discussed is SRC; the disease is malignant colon neoplasm.